lilly-logo-2--1
Photo: Courtesy of Eli Lilly
23 August 2016Americas

AstraZeneca and Eli Lilly’s Alzheimer’s treatment to be fast tracked

AstraZeneca and Eli Lilly have received US Food and Drug Administration (FDA) fast track designation for the development of a treatment for Alzheimer’s.

The companies made the announcement yesterday, August 22.

The FDA’s fast track programme is designed to expedite the development of new therapies that treat serious conditions.

Craig Shering, project lead in global medicines development at AstraZeneca, said: “The fast track designation in the US for this promising potential therapy reinforces the ambition of the AstraZenaca-Lilly BACE Alliance to advance science for patients and their families managing this devastating illness.”

Phyllis Ferrell, vice president at Eli Lilly, added: “We are pleased that the FDA places a high priority on the development of drugs that target Alzheimer’s disease, one of the most critical health issues of our time.”

AstraZeneca and Eli Lilly agreed to develop and commercialise the Alzheimer's treatment back in 2014, with Eli Lilly leading clinical development and AstraZeneca responsible for manufacturing.


More on this story

Americas
22 October 2020   Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.
Americas
22 July 2021   The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

More on this story

Americas
22 October 2020   Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.
Americas
22 July 2021   The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.